MEK AND PI3K INHIBITION IN THE REGULATION OF PANCREATIC CANCER METABOLISM

$437,090P01FY2012CANIH

University Of Tx Md Anderson Can Ctr, Houston TX

Investigators

Linked publications & trials

Paper 39536083 Paper 39468013 Paper 39232498 Paper 39211217 Paper 38991060 Paper 38985503 Paper 38843329 Paper 38816352 Paper 38802576 Paper 38798370 Paper 38720073 Paper 38714664 Paper 38467382 Paper 38280869 Paper 37942963 Paper 37814010 Paper 37775182 Paper 37696660 Paper 37676964 Paper 37625403 Paper 37625401 Paper 37312426 Paper 37190324 Paper 37174073 Paper 37140994 Paper 37075122 Paper 37069394 Paper 37069167 Paper 37026453 Paper 36935322 Paper 36746143 Paper 36631611 Paper 36585453 Paper 36282600 Paper 36231030 Paper 35868307 Paper 35726190 Paper 35412885 Paper 35348629 Paper 35022962 Paper 34893625 Paper 34889852 Paper 34819622 Paper 34531315 Paper 34529467 Paper 34489603 Paper 34471290 Paper 34429247 Paper 34385458 Paper 34142094 Paper 34117030 Paper 34040169 Paper 33930309 Paper 33905375 Paper 33852841 Paper 33839689 Paper 33742165 Paper 33667385 Paper 33531365 Paper 33504580 Paper 33406434 Paper 33158812 Paper 33152323 Paper 33142117 Paper 33027658 Paper 32967217 Paper 32376951 Paper 32341021 Paper 32341020 Paper 32046984 Paper 31980749 Paper 31942075 Paper 31919052 Paper 31827279 Paper 31663852 Paper 31557131 Paper 31488580 Paper 31406347 Paper 31316073 Paper 31185211 Paper 31134896 Paper 30925917 Paper 30918400 Paper 30905761 Paper 30833752 Paper 30642914 Paper 30635425 Paper 30614183 Paper 30609754 Paper 30470748 Paper 30120146 Paper 30051890 Paper 29941929 Paper 29925948 Paper 29871934 Paper 29769196 Paper 29731362 Paper 29727621 Paper 29702208 Paper 29669940

Abstract

The vast majority of pancreatic ductal adenocarcinomas (PDAC) involve activating mutations in KRAS (KRAS*) and as with other KRAS* cancers, PDAC show minimal response to existing therapies used in the clinic. While no satisfactory KRAS*-speclfic drugs are currently available, inhibitors of MEK and PI3K (MEKi and PI3Ki)¿pathways necessary for KRAS*-mediated cellular transformation in vitro, are now being introduced into clinical trials. The central hypothesis guiding this project is that PDAC utilize the PI3K and MEK pathways In a redundant way to drive tumor growth and that a critical role for these pathways Involves the regulation of tumor metabolism. The overall goals of this proposal are to determine the impact of MEKi/PI3Ki on PDAC cell signaling, metabolism, and therapeutic response. These efforts will be coupled with an investigation of metabolic biomarkers for MEK/PI3K signaling and identification of mechanisms of therapeutic resistance which would be critical in future therapeutic trials. The Aims are: 1. Determine the impact of MEK/PI3K inhibition in PDAC. Genetically engineered mouse models as well as genomically characterized organotypic human PDAC cultures will be used to compare the cellular responses and signaling pathway alterations provoked by genetic or pharmacologic MEKi/PI3Ki against the backdrop of different combinations of tumor suppressor mutations found in human PDAC. 2. Determine the impact of MEK/PISK inhibition on PDAC metabolism. Glutamine and glucose are the main nutrients used by tumor cells for energy generation and for anabolic processes. The contribution of these nutrients to PDAC metabolism in vivo and the impact of MEKi/PI3Ki on their utilization will be determined using a series of radioisotope labeling, molecular imaging, and LC-MS approaches. These studies will give insight Into the regulation of PDAC metabolism and define biomarkers for the activity of these pathways. 3. Determine the mechanisms of resistance to MEKi/PI3Ki in PDAC. Preliminary studies indicate that mouse PDAC models will eventually develop acquired resistance to MEKi/PI3Ki. The mechanisms of acquired resistance will be explored by a series of phosphoproteomics and genetic analyses. In addition, as a means to increase the bi

View original record on NIH RePORTER →